Delivery Order SPE2DR25D1103-SPE2DR26FE229
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,979.90 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL units, with an ultimate completion date of December 1, 2025. This non-competitive delivery order represents a firm fixed-price transaction under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be performed at the vendor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $4,852.12 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $8,457.75 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens, 80 mg/0.8 mL formulation. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of December 5, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, due for completion by June 2, 2025. The award was issued on May 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $9,191.44 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL doses. This firm fixed-price delivery order, awarded on November 24, 2025, with an ultimate completion date of November 25, 2025, was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $2,776.98 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL on November 28, 2025, with completion scheduled for December 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens (40 mg/0.4 mL) valued at $2,265.90 with a firm fixed price contract type. This award, issued November 5, 2025, is a non-set-aside competitive procurement executed as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle supporting pharmaceutical procurement through December 2026. The...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,434.52 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. The contract, designated as a firm fixed-price delivery order, was competitively awarded with no set-aside provisions and carries an ultimate completion date of December 4, 2025. AmerisourceBergen will perform the work from its corporate headquarters in Conshohocken, Pennsylvania. This award is a child order issued under...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE229Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,387.94 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL formulation. This non-competitive, firm fixed-price delivery order was issued on December 5, 2025, with an ultimate completion date of December 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply requirements, likely for military or defense healthcare operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical prime vendor agreement running through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies to support defense health operations globally. The company's federal contracting demonstrates consistent capability to fulfill competitive pharmaceutical procurement requirements across multiple therapeutic domains for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 12/4/25 |